Intra-articular injection of chitosan combined with low-dose glucocorticoid for the treatment of knee osteoarthritis in early and middle stages

Jiuxiang Liu,Xiaowen Huang,Tianrun Lv,Liang Cao,Lu Lu
DOI: https://doi.org/10.1097/md.0000000000039924
IF: 1.6
2024-10-09
Medicine
Abstract:Osteoarthritis (OA) can cause joint pain, limited activity, and functional impairment. It is a chronic disease that seriously affects the quality of life of middle-aged and elderly people. [ 1–5 ] At present, the incidence of OA in people over 40 years old in China is close to 50%, and it is increasing year by year with aging, causing serious social and economic burdens. [ 4 , 6 ] The knee joint is the most commonly involved. According to the principle of step-by-step treatment, most patients with knee osteoarthritis (KOA) choose conservative treatment. At present, topical and oral nonsteroidal anti-inflammatory drugs (NSAIDs) are still the first-line treatment options, but there are risks of poor oral medication effect, long medication time, easy recurrence of symptoms after stopping medication, local medication can easily cause skin reactions, and potential cardiovascular and gastrointestinal adverse events. [ 1–5 ] Intra-articular injection is a treatment method of direct medication at the lesion, with small trauma, quick effect, and avoids the disadvantages of topical and oral medication. It is increasingly valued in clinical practice and is confirmed by the guidelines as a first-line treatment option. There are various types of drugs for intra-articular injection, each with its advantages and disadvantages. The recommendations of domestic and foreign guidelines are different, and no consensus has been reached. [ 7 ] Chitosan, as a newer drug, has good tissue compatibility and biological activity, and is gradually used for intra-articular injection, but there are still few clinical reports at home and abroad. This study retrospectively analyzed the clinical efficacy of chitosan combined with low-dose glucocorticoid intra-articular injection in the treatment of KOA early and middle stages in our hospital from June 2021 to 2023, and now reports as follows.
medicine, general & internal
What problem does this paper attempt to address?